296 related articles for article (PubMed ID: 32058159)
1. Relationships of inflamm-aging with circulating nutrient levels, body composition, age, and pituitary pars intermedia dysfunction in a senior horse population.
Siard-Altman MH; Harris PA; Moffett-Krotky AD; Ireland JL; Betancourt A; Barker VD; McMurry KE; Reedy SE; Adams AA
Vet Immunol Immunopathol; 2020 Mar; 221():110013. PubMed ID: 32058159
[TBL] [Abstract][Full Text] [Related]
2. Cytokine dysregulation in aged horses and horses with pituitary pars intermedia dysfunction.
McFarlane D; Holbrook TC
J Vet Intern Med; 2008; 22(2):436-42. PubMed ID: 18371032
[TBL] [Abstract][Full Text] [Related]
3. Effects of advanced age and pituitary pars intermedia dysfunction on components of the acute phase reaction in horses.
Zak A; Siwinska N; Elzinga S; Barker VD; Stefaniak T; Schanbacher BJ; Place NJ; Niedzwiedz A; Adams AA
Domest Anim Endocrinol; 2020 Jul; 72():106476. PubMed ID: 32380311
[TBL] [Abstract][Full Text] [Related]
4. Investigation of rhythms of secretion and repeatability of plasma adrenocorticotropic hormone concentrations in healthy horses and horses with pituitary pars intermedia dysfunction.
Rendle DI; Litchfield E; Heller J; Hughes KJ
Equine Vet J; 2014 Jan; 46(1):113-7. PubMed ID: 23742059
[TBL] [Abstract][Full Text] [Related]
5. Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia.
Beech J; Boston R; Lindborg S; Russell GE
J Am Vet Med Assoc; 2007 Aug; 231(3):417-26. PubMed ID: 17669045
[TBL] [Abstract][Full Text] [Related]
6. Pituitary pars intermedia dysfunction does not necessarily impair insulin sensitivity in old horses.
Mastro LM; Adams AA; Urschel KL
Domest Anim Endocrinol; 2015 Jan; 50():14-25. PubMed ID: 25240230
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of combined testing to simultaneously diagnose pituitary pars intermedia dysfunction and insulin dysregulation in horses.
Horn R; Bertin FR
J Vet Intern Med; 2019 Sep; 33(5):2249-2256. PubMed ID: 31498947
[TBL] [Abstract][Full Text] [Related]
8. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.
Miller AB; Loynachan AT; Bush HM; Hart KA; Barker VD; Campana-Emard AG; Grubbs ST; Adams AA
Domest Anim Endocrinol; 2021 Jan; 74():106531. PubMed ID: 32942194
[TBL] [Abstract][Full Text] [Related]
9. Association of season and pasture grazing with blood hormone and metabolite concentrations in horses with presumed pituitary pars intermedia dysfunction.
Frank N; Elliott SB; Chameroy KA; Tóth F; Chumbler NS; McClamroch R
J Vet Intern Med; 2010; 24(5):1167-75. PubMed ID: 20666984
[TBL] [Abstract][Full Text] [Related]
10. α-Melanocyte--stimulating hormone and adrenocorticotropin concentrations in response to thyrotropin-releasing hormone and comparison with adrenocorticotropin concentration after domperidone administration in healthy horses and horses with pituitary pars intermedia dysfunction.
Beech J; McFarlane D; Lindborg S; Sojka JE; Boston RC
J Am Vet Med Assoc; 2011 May; 238(10):1305-15. PubMed ID: 21568777
[TBL] [Abstract][Full Text] [Related]
11. BEVA primary care clinical guidelines: Diagnosis and management of equine pituitary pars intermedia dysfunction.
Menzies-Gow NJ; Banse HE; Duff A; Hart N; Ireland JL; Knowles EJ; McFarlane D; Rendle D
Equine Vet J; 2024 Mar; 56(2):220-242. PubMed ID: 37795557
[TBL] [Abstract][Full Text] [Related]
12. Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction.
Fortin JS; Benskey MJ; Lookingland KJ; Patterson JS; Howey EB; Goudreau JL; Schott HC
BMC Vet Res; 2020 Sep; 16(1):356. PubMed ID: 32977825
[TBL] [Abstract][Full Text] [Related]
13. Comparison of cortisol and ACTH responses after administration of thyrotropin releasing hormone in normal horses and those with pituitary pars intermedia dysfunction.
Beech J; Boston R; Lindborg S
J Vet Intern Med; 2011; 25(6):1431-8. PubMed ID: 22092639
[TBL] [Abstract][Full Text] [Related]
14. Equine pituitary pars intermedia dysfunction: a spontaneous model of synucleinopathy.
Fortin JS; Hetak AA; Duggan KE; Burglass CM; Penticoff HB; Schott HC
Sci Rep; 2021 Aug; 11(1):16036. PubMed ID: 34362943
[TBL] [Abstract][Full Text] [Related]
15. Whole-body phenylalanine kinetics and skeletal muscle protein signaling in horses with pituitary pars intermedia dysfunction.
Mastro LM; Adams AA; Urschel KL
Am J Vet Res; 2014 Jul; 75(7):658-67. PubMed ID: 24959733
[TBL] [Abstract][Full Text] [Related]
16. Lamellar pathology in horses with pituitary pars intermedia dysfunction.
Karikoski NP; Patterson-Kane JC; Singer ER; McFarlane D; McGowan CM
Equine Vet J; 2016 Jul; 48(4):472-8. PubMed ID: 25869529
[TBL] [Abstract][Full Text] [Related]
17. The use of adrenocorticotrophic hormone as a potential biomarker of pituitary pars intermedia dysfunction in horses.
Lee ZY; Zylstra R; Haritou SJ
Vet J; 2010 Jul; 185(1):58-61. PubMed ID: 20537574
[TBL] [Abstract][Full Text] [Related]
18. Circannual variation in plasma adrenocorticotropic hormone concentrations in the UK in normal horses and ponies, and those with pituitary pars intermedia dysfunction.
Copas VE; Durham AE
Equine Vet J; 2012 Jul; 44(4):440-3. PubMed ID: 21848531
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the effects of age and pituitary pars intermedia dysfunction on corneal sensitivity in horses.
Miller C; Utter ML; Beech J
Am J Vet Res; 2013 Jul; 74(7):1030-5. PubMed ID: 23802675
[TBL] [Abstract][Full Text] [Related]
20. The effect of freeze-thaw cycles on determination of immunoreactive plasma adrenocorticotrophic hormone concentrations in horses.
Hu K; Stewart AJ; Yuen KY; Hinrichsen S; Dryburgh EL; Bertin FR
J Vet Intern Med; 2020 May; 34(3):1350-1356. PubMed ID: 32255541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
